• ABRAXANE should not be used in patients who have baseline
neutrophil counts of <1500 cells/mm3
• Patients who experience a severe hypersensitivity reaction to
ABRAXANE should not be rechallenged with the drug
WARNINGS AND PRECAUTIONS
• Bone marrow suppression (primarily neutropenia) is dose-dependent
and a dose-limiting toxicity of ABRAXANE. In clinical studies, Grade 3-4
neutropenia occurred in 34% of patients with metastatic breast cancer
(MBC), 47% of patients with non–small cell lung cancer (NSCLC), and
38% of patients with pancreatic cancer
WARNING - NEUTROPENIA
• Do not administer ABRAXANE therapy to patients who
have baseline neutrophil counts of less than 1500 cells/mm3.
In order to monitor the occurrence of bone marrow
suppression, primarily neutropenia, which may be severe
and result in infection, it is recommended that frequent
peripheral blood cell counts be performed on all patients
• Note: An albumin form of paclitaxel may substantially affect
a drug’s functional properties relative to those of drug
in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER
ABRAXANE is indicated for the
first-line treatment of patients with
metastatic adenocarcinoma of
the pancreas (MPAC), in combination
ABRAXANE is indicated for the first-line
treatment of locally advanced or metastatic
non–small cell lung cancer (NSCLC),
in combination with carboplatin, in patients
who are not candidates for curative surgery
or radiation therapy.
ABRAXANE is indicated for the treatment
of breast cancer after failure of combination
chemotherapy for metastatic disease or relapse
within 6 months of adjuvant chemotherapy.
Prior therapy should have included an
anthracycline unless clinically contraindicated.
Important Safety Information
indications ignited we stand with
Please see additional Important Safety Information and Brief Summary for ABRAXANE, including
Boxed WARNING, on following pages.